{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:16Z","timestamp":1791994576470,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011002","name":"National Natural Science Foundation of China-Yunnan Joint Fund","doi-asserted-by":"publisher","award":["82103746"],"award-info":[{"award-number":["82103746"]}],"id":[{"id":"10.13039\/501100011002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018627","name":"Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.intimp.2023.110591","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T16:43:50Z","timestamp":1689093830000},"page":"110591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9336-1985","authenticated-orcid":false,"given":"Hongda","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guizhi","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2184-8030","authenticated-orcid":false,"given":"Futang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2023.110591_b0005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2133.2011.10386.x","article-title":"Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study","volume":"165","author":"Chen","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110591_b0010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fmed.2018.00222","article-title":"Interaction of Psoriasis and Bullous Diseases","volume":"5","author":"Dainichi","year":"2018","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.110591_b0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaad.2015.03.016","article-title":"Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases","volume":"73","author":"Ohata","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110591_b0020","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2017.02.057","article-title":"Association between bullous pemphigoid and psoriasis: A case-control study","volume":"77","author":"Kridin","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110591_b0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ajd.12899","article-title":"Association between bullous pemphigoid and psoriasis: Systematic review and meta-analysis of case-control studies","volume":"60","author":"Phan","year":"2019","journal-title":"Australas. J. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110591_b0030","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/bjd.12072","article-title":"British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012","volume":"167","author":"Venning","year":"2012","journal-title":"Brit. J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110591_b0035","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/bjd\/ljac078","article-title":"Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases","volume":"188","author":"Fan","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.intimp.2023.110591_b0040","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jamaophthalmol.2018.3789","article-title":"Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib","volume":"136","author":"Sarny","year":"2018","journal-title":"JAMA ophthalmology"},{"key":"10.1016\/j.intimp.2023.110591_b0045","article-title":"Tofacitinib for refractory ocular mucous membrane pemphigoid","volume":"22","author":"James","year":"2021","journal-title":"Am. J. Ophthalmol. Case Rep."},{"issue":"10","key":"10.1016\/j.intimp.2023.110591_b0050","doi-asserted-by":"crossref","first-page":"e15754","DOI":"10.1111\/dth.15754","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2023.110591_b0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","article-title":"JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors","volume":"80","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2023.110591_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.110591_b0065","first-page":"10","article-title":"Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases","volume":"2019","author":"Szilveszter","year":"1862","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110591_b0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic Treatment of Psoriasis with JAK Inhibitors: A Review","volume":"10","author":"Kvist-Hansen","year":"2020","journal-title":"Dermatol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2023.110591_b0075","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2017.07.027","article-title":"Tofacitinib Is the Right OCTAVE for Ulcerative Colitis","volume":"153","author":"Pouillon","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2023.110591_b0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.intimp.2023.110591_b0085","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.110591_b0090","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","article-title":"New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update","volume":"10","author":"Genovese","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110591_b0095","doi-asserted-by":"crossref","unstructured":"S. LE JAN, J. PL\u00e9E, D. Vallerand, et al. Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid, J. Investigative Dermatol., 2014, 134(12): 2908-17.","DOI":"10.1038\/jid.2014.263"},{"issue":"12","key":"10.1016\/j.intimp.2023.110591_b0100","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1600-0625.2011.01378.x","article-title":"Lesional Th17 cells and regulatory T cells in bullous pemphigoid","volume":"20","author":"Arakawa","year":"2011","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.intimp.2023.110591_b0105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid","volume":"96","author":"Chakievska","year":"2019","journal-title":"J. Autoimmun."},{"issue":"15","key":"10.1016\/j.intimp.2023.110591_b0110","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted Therapies for Autoimmune Bullous Diseases: Current Status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.intimp.2023.110591_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102661","article-title":"The role of T cells in pemphigus vulgaris and bullous pemphigoid","volume":"19","author":"Fang","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"10.1016\/j.intimp.2023.110591_b0120","doi-asserted-by":"crossref","first-page":"e1519","DOI":"10.1002\/mgg3.1519","article-title":"TH17\/IL23 cytokine gene polymorphisms in bullous pemphigoid","volume":"8","author":"Tabatabaei-Panah","year":"2020","journal-title":"Mol. Genet. Genomic Med."},{"issue":"4","key":"10.1016\/j.intimp.2023.110591_b0125","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.smim.2013.10.009","article-title":"The plasticity of human Treg and Th17 cells and its role in autoimmunity","volume":"25","author":"Kleinewietfeld","year":"2013","journal-title":"Semin. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110591_b0130","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2023.110591_b0135","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.110591_b0140","doi-asserted-by":"crossref","unstructured":"A.K. ALVES DE MEDEIROS, R. SPEECKAERT, E. DESMET, et al. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases. PloS one, 2016, 11(10): e0164080.","DOI":"10.1371\/journal.pone.0164080"},{"issue":"1","key":"10.1016\/j.intimp.2023.110591_b0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nm1162","article-title":"Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model","volume":"11","author":"Sano","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.110591_b0150","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus Kinase Family in Autoimmune Skin Diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110591_b0155","doi-asserted-by":"crossref","first-page":"6716419","DOI":"10.1155\/2017\/6716419","article-title":"Expression of the JAK\/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis","volume":"2017","author":"Juczynska","year":"2017","journal-title":"Mediators Inflamm."},{"issue":"19","key":"10.1016\/j.intimp.2023.110591_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194307","article-title":"Role of Janus Kinase Inhibitors in Therapy of Psoriasis","volume":"10","author":"S\u0142uczanowska-G\u0142\u0105bowska","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2023.110591_b0165","doi-asserted-by":"crossref","unstructured":"J.E. Hawkes, B.Y. Yan, T.C. Chan, et al. Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis. Journal of immunology (Baltimore, Md : 1950), 2018, 201(6): 1605-13.","DOI":"10.4049\/jimmunol.1800013"},{"issue":"3","key":"10.1016\/j.intimp.2023.110591_b0170","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110591_b0175","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"di Cesare","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110591_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010179","article-title":"Scanning the Immunopathogenesis of Psoriasis","volume":"19","author":"Chiricozzi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2023.110591_b0185","doi-asserted-by":"crossref","unstructured":"A. Hald, R.M. ANDR\u00e9S, M.L. Salskov-Iversen, et al. STAT1 expression and activation is increased in lesional psoriatic skin, British J. Dermatol., 2013, 168(2): 302-10.","DOI":"10.1111\/bjd.12049"},{"issue":"5","key":"10.1016\/j.intimp.2023.110591_b0190","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2023.110591_b0195","doi-asserted-by":"crossref","unstructured":"M.A. Lowes, M. SU\u00e1REZ-FARI\u00f1AS, J.G. Krueger, Immunology of psoriasis, Ann. Rev. Immunol., 2014, 32: 227-55.","DOI":"10.1146\/annurev-immunol-032713-120225"},{"key":"10.1016\/j.intimp.2023.110591_b0200","doi-asserted-by":"crossref","unstructured":"J. Loget, J. PL\u00e9E, F. Antonicelli, et al. A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis, J. Eur. Acad. Dermatol. Venereol. : JEADV, 2017, 31(5): e228-e30.","DOI":"10.1111\/jdv.14002"},{"issue":"5","key":"10.1016\/j.intimp.2023.110591_b0205","doi-asserted-by":"crossref","first-page":"e12696","DOI":"10.1111\/dth.12696","article-title":"Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus","volume":"31","author":"Tavakolpour","year":"2018","journal-title":"Dermatol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2023.110591_b0210","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/13543776.2019.1567713","article-title":"Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015\u20132018)","volume":"29","author":"He","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"issue":"5","key":"10.1016\/j.intimp.2023.110591_b0215","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110591_b0220","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"9993","key":"10.1016\/j.intimp.2023.110591_b0225","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.intimp.2023.110591_b0230","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2023.110591_b0235","doi-asserted-by":"crossref","unstructured":"J. Krueger, J.D. Clark, M. SU\u00e1REZ-FARI\u00f1AS, et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study, J. Allergy Clin. Immunol., 2016, 137(4): 1079-90.","DOI":"10.1016\/j.jaci.2015.12.1318"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923009165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923009165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:22:28Z","timestamp":1736432548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923009165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":47,"alternative-id":["S1567576923009165"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110591","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110591"}}